
Citing NIH cuts, a top science journal stops accepting submissions
'If the journal is indeed lost, it is a huge loss,' said Jonathan Levy, chair of the department of environmental health at Boston University. 'It's reducing the ability for people to have good information that can be used to make good decisions.'
Get Starting Point
A guide through the most important stories of the morning, delivered Monday through Friday.
Enter Email
Sign Up
The news comes weeks after a federal prosecutor in Washington sent letters to several scientific journals, including The New England Journal of Medicine, with questions that suggested that they were biased against certain views and influenced by external pressures.
Advertisement
The editor of The New England Journal of Medicine described the letter as 'vaguely threatening.' On Tuesday, the journal Obstetrics and Gynecology, published by the American College of Obstetricians and Gynecologists, said that it had received such a letter.
Scientific journals have long been a target of top health officials in the Trump administration.
In a book published last year, Dr. Marty Makary, the new commissioner of the Food and Drug Administration, accused journal editorial boards of 'gate-keeping' and publishing only information that supports a 'groupthink narrative.'
Advertisement
In an interview with the 'Dr. Hyman Show' podcast last year, Robert F. Kennedy Jr., who is now secretary of health and human services, said he planned to prosecute medical journals under federal anti-corruption laws.
'I'm going to find a way to sue you unless you come up with a plan right now to show how you're going to start publishing real science,' he said.
Still, the announcement regarding Environmental Health Perspectives baffled researchers, who pointed out that the funding cuts seemed to conflict with the Trump administration's stated priorities.
For instance, Kennedy has repeatedly emphasized the importance of studying the environment's role in causing chronic diseases. The new administration has also expressed interest in the transparency and public accessibility of scientific journals, an area in which Environmental Health Perspectives has been a trailblazer.
Environmental Health Perspectives was one of the first 'open-access' journals, allowing anyone to read without a subscription. And unlike many other open-access journals, which often charge researchers thousands of dollars to publish their work, Environmental Health Perspectives' federal support meant scientists from smaller universities could publish without worrying about a fee.
'There are multiple layers of irony here,' Levy said.
Environmental Health Perspectives isn't the only journal caught in the crossfire of funding cuts at the Department of Health and Human Services.
A draft budget for the department, obtained by The New York Times, proposes axing two journals published by the Centers for Disease Control and Prevention: Emerging Infectious Diseases and Preventing Chronic Disease. Both are published free of charge to authors and readers and are among the top journals in their fields.
Advertisement
Andrew Nixon, an HHS spokesperson, said 'no final decision has been made' about the upcoming budget.
Emerging Infectious Diseases, published monthly, provides cutting-edge reports on infectious disease threats from around the world.
It has helped to shape preparedness and response to outbreaks, said Jason Kindrachuk, a virus expert at the University of Manitoba who has published research on the Marburg and mpox viruses in the journal.
The news 'is very disheartening,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock
UnitedHealth Group Incorporated (NYSE:UNH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On August 7, Mizuho analyst Ann Hynes kept her 'Buy' rating, expecting long-term value despite reducing the price objective to $300. The analyst noted that the company has reinstated its 2025 earnings guidance. The analyst believes that pricing pressure and increased medical cost trends will continue into 2026. Furthermore, the analyst also highlighted the underperformance in Optum Health's value-based care and Optum Insight segments. Despite these factors, Hynes opines that UnitedHealth Group Incorporated (NYSE:UNH)'s scale, market position, and diversified business are the key strengths, and believes that the stock's valuation is attractive. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH)'s Q2 2025 revenues increased $12.8 billion YoY to $111.6 billion. This was aided by growth in UnitedHealthcare and Optum. Notably, the Q2 2025 consolidated medical care ratio stood at 89.4%, reflecting an increase of 430 bps YoY. This was mainly because of medical cost trends, which significantly surpassed pricing trends, such as both unit costs and the intensity of services delivered, and the ongoing impacts of Medicare funding reductions. Hotchkis & Wiley, an investment management company, released its Q2 2025 investor letter and mentioned UnitedHealth Group Incorporated (NYSE:UNH). Here is what the fund said: 'UnitedHealth Group Incorporated (NYSE:UNH) is a large US health insurer. Until very recently, UNH traded at a material premium to its peers, reflecting its status as a premium growth stock with momentum. We did not own the stock. However, recent negative headlines, combined with the first earnings miss in 10 years, resulted in a >50% selloff in the company's shares. This decline contributed positively to the strategy's relative performance vs. the index, where UNH was a meaningful weight. We purchased UNH shares after the selloff at what we believe is a compelling valuation.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 hours ago
- Yahoo
Mizuho Keeps Buy Rating on UnitedHealth Group (UNH) Stock
UnitedHealth Group Incorporated (NYSE:UNH) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On August 7, Mizuho analyst Ann Hynes kept her 'Buy' rating, expecting long-term value despite reducing the price objective to $300. The analyst noted that the company has reinstated its 2025 earnings guidance. The analyst believes that pricing pressure and increased medical cost trends will continue into 2026. Furthermore, the analyst also highlighted the underperformance in Optum Health's value-based care and Optum Insight segments. Despite these factors, Hynes opines that UnitedHealth Group Incorporated (NYSE:UNH)'s scale, market position, and diversified business are the key strengths, and believes that the stock's valuation is attractive. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH)'s Q2 2025 revenues increased $12.8 billion YoY to $111.6 billion. This was aided by growth in UnitedHealthcare and Optum. Notably, the Q2 2025 consolidated medical care ratio stood at 89.4%, reflecting an increase of 430 bps YoY. This was mainly because of medical cost trends, which significantly surpassed pricing trends, such as both unit costs and the intensity of services delivered, and the ongoing impacts of Medicare funding reductions. Hotchkis & Wiley, an investment management company, released its Q2 2025 investor letter and mentioned UnitedHealth Group Incorporated (NYSE:UNH). Here is what the fund said: 'UnitedHealth Group Incorporated (NYSE:UNH) is a large US health insurer. Until very recently, UNH traded at a material premium to its peers, reflecting its status as a premium growth stock with momentum. We did not own the stock. However, recent negative headlines, combined with the first earnings miss in 10 years, resulted in a >50% selloff in the company's shares. This decline contributed positively to the strategy's relative performance vs. the index, where UNH was a meaningful weight. We purchased UNH shares after the selloff at what we believe is a compelling valuation.' While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
3 hours ago
- Yahoo
Canaccord Lowers Clover Health (CLOV) PT to $4.10 Despite Strong Q2 Growth
Clover Health Investments Corp. (NASDAQ:CLOV) is one of the most promising penny stocks under $5. On August 7, Canaccord lowered the firm's price target on Clover Health to $4.10 from $4.50, while keeping a Buy rating on the shares. The firm said the company reported solid Q2 2025 results, but the insurance benefit expense ratio came in higher than expected, which was of some concern. In Q2, the company's Medicare Advantage membership grew by over 30% year-over-year, and the insurance revenue increased by 34% to $470 million. Clover Health Investments' technology-first care model, which includes the Clover Assistant platform, showed a 15% reduction in hospitalizations and an 18% reduction in readmissions for patients with chronic obstructive pulmonary disease/COPD. An older Medicare-eligible consumer smiling happily while receiving healthcare services at a clinic. The company is now well-positioned for future growth with a 4-star payment year in 2026, which is expected to provide a financial tailwind. Clover Health is also expanding its technology platform to other risk-bearing entities, potentially opening up additional revenue streams. Clover Health Investments Corp. (NASDAQ:CLOV) is a company that provides medicare advantage plans in the US. It operates Clover Assistant, which is a software platform to execute strategy by enabling physicians to detect, identify, and manage chronic diseases earlier than they otherwise could. While we acknowledge the potential of CLOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data